TY -的A2避开Chia-Tung盟——马匹,罗伯托·非盟- Calogero,奥尔多·e . AU - Vicari恩佐盟——Calabrini乔凡娜盟——张家港基地,安娜AU - D 'Agati,普拉西多盟,Fraggetta菲利普盟——生活米歇尔PY - 2020 DA - 2020/06/29 TI -聚(ADP-Ribose)聚合酶1蛋白表达在正常胰腺,胰腺腺癌SP - 2717150六世- 2020 AB -胰腺癌是一种最常见癌症在欧洲,大多数情况下的胰腺癌诊断65岁以上。根治手术是第一个治疗胰腺癌的治疗和替代或联合治疗选项,特别是,由辅助或新辅助化疗,有或没有放射治疗。许多因素,包括饮食和基因,已经与胰腺癌的发展。保利(ADP-ribose)聚合酶1 (PARP-1)蛋白质的易位需要从线粒体凋亡诱导因子(AIF)细胞核。它参与细胞程序性死亡过程。不同PARP-1基因表达的蛋白质已观察到各种肿瘤,如肺癌、卵巢癌、子宫内膜癌、皮肤,胶质母细胞瘤。我们评估PARP-1蛋白的表达在胰腺腺癌和正常胰腺组织的免疫组织化学。细胞核被发现在所有样品中蛋白质PARP-1(正常胰腺及胰腺腺癌组织)。没有细胞质染色观察样本。PARP-1-positive细胞导致更高的在正常胰腺与胰腺腺癌。 PARP-1 overexpression in prostate cancer tissue compared with normal prostate suggests a greater activity of PARP-1 in these tumors. These findings suggest that PARP-1 expression in prostate cancer is an attempt to trigger apoptosis in this type of tumor, similarl to that reported in other cancers. This finding suggests that PARP-1-mediated cell death pathways are inhibited in this cancer. SN - 2090-6528 UR - https://doi.org/10.1155/2020/2717150 DO - 10.1155/2020/2717150 JF - Case Reports in Gastrointestinal Medicine PB - Hindawi KW - ER -